Clinical Trial

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Study acronym: EIK1004-001
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-31; most recent amendment 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2025-05-14
Trial Details
NCT Number NCT06907043
Lead Sponsor Eikon Therapeutics
Collaborators: Impact Therapeutics, Inc.
Conditions Advanced Solid Tumors
Enrollment 130 participants
Start Date 2025-04-30
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-19